Floatz logo

Phentermine

Craniopharyngioma

Seattle Children's HospitalSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Craniopharyngioma cohort.

Asset / SponsorPhaseRating
Exenatide
University Hospital, Bordeaux
Phase 3BB
Irinotecan
National Cancer Institute (NCI)
Phase 2BB
Eudemine Injection
Assistance Publique - Hôpitaux de Paris
Phase 3BB
Oxytocin
Shana McCormack, MD
Phase 2B
Beloranib
Zafgen, Inc.
Phase 2CCC

View all 20 →

Same molecule, other indications

Phentermine is also rated in:

obesity disorderActive
BBB
Indicative · Phase 4
73 / 100
View asset →
essential hypertensionActive
BB
Indicative · Phase 4
69 / 100
View asset →
morbid obesityDormant
BB
Indicative · Phase 4
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →